Project Grant R21AI199416
Award Date 8/3/26
Completion Date 7/31/28
Dollars Obligated $224K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University $448,089 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test engineered extracellular vesicles (EVs) as a tolerogenic immunotherapy platform for autoimmune disease. The funded work focuses on engineering EVs derived from mesenchymal stem cells to deliver autoantigens in a tolerogenic context, with initial testing in a multiple sclerosis model....
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vanderbilt University Medical Center a Project Grant of $751,138 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 16, 2025, with completion targeted for June 30, 2030. This award supports basic immunological research investigating the role of glutaminase-dependent metabolism in dendritic cells and its contribution to inflammatory diseases and immune...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $274,991 on May 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial membrane fusion sustains commensal resilience during enteric pathogen infection. The research examines molecular mechanisms by which commensal bacteria in the human gut withstand or recover from perturbations caused by enteric infections, particularly how Bacteroides...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University $152,600 on November 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on targeted delivery of STING agonists to regulatory T cells for cancer immunotherapy. The project, designated F32AI200412, focuses on engineering a bispecific nanobody-STING agonist conjugate designed to selectively reprogram regulatory T cells to enhance anti-tumor immunity while minimizing...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $262,388 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the RNA binding protein HNRNPA2B1 regulates macrophage responses to Mycobacterium tuberculosis infection. The research examines alternative splicing as a mechanism controlling the balance between MTB virulence and host antimicrobial defenses. The award funds work to define how...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $622,476 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate metabolic mechanisms of regulatory T cell dysfunction in atherosclerosis. The research examines how oxidized phospholipids accumulate in atherosclerotic plaques and impair the protective function of T regulatory cells (Tregs) that normally suppress chronic arterial inflammation....
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $153,560 on October 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate subcellular compartmentalization of sulfur metabolism in Acinetobacter baumannii, a bacterial pathogen responsible for 15–25 percent of ventilator-associated pneumonia cases in hospitals. The research examines how A. baumannii regulates sulfur uptake and metabolism during...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $481,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 16, 2025 through June 30, 2027. The award supports research investigating human rotavirus egress and infection in association with extracellular vesicles (EVs)—membrane-bound structures released from cells that can transport viral...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University $140,496 on January 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of cytochrome BD in supporting flagellar motility in uropathogenic Escherichia coli. The research elucidates connections between bacterial aerobic respiration and flagellar motility in UPEC, the primary cause of urinary tract infections, with the goal of identifying pathways essential...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University $105,216 on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of lipid-laden macrophages in Staphylococcus aureus osteomyelitis abscess formation. The research employs multimodal imaging techniques, including matrix-assisted laser desorption/ionization imaging mass spectrometry, to examine the spatial localization and physiology of...